+ Evidence in focus

Arthroplasty registry analysis 2025

SmithNephew

Comparison of survivorship for OXINIUM^o/XLPE with other bearing combinations in primary THA: review of international registry data


Key points





OXINIUM/XLPE has the highest survivorship of all bearing combinations at 20 years1

Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR)





								20 Yrs
Ceramic/Ceramic	5437	114611	1.4 (1.4, 1.5)	2.3 (2.2, 2.4)	2.9 (2.8, 3.0)	4.5 (4.4, 4.7)	6.5 (6.3, 6.7)	8.8 (8.5, 9.2)
Ceramic/Non XLPE	799	11499	1.8 (1.5, 2.0)	3.0 (2.7, 3.3)	3.5 (3.2, 3.9)	6.6 (6.0, 7.2)	11.0 (10.1, 11.9)	15.6 (14.4, 16.9)
Ceramic/XLPE	5456	191223	1.7 (1.6, 1.7)	2.4 (2.3, 2.5)	2.8 (2.8, 2.9)	4.0 (3.9, 4.1)	5.4 (5.2, 5.7)	6.7 (6.2, 7.2)
Ceramic/Metal	31	299	1.7 (0.7, 4.0)	3.7 (2.1, 6.6)	4.4 (2.6, 7.4)	8.3 (5.7, 12.2)	11.4 (8.1, 15.9)	
Metal/Metal >32mm	3931	14424	1.7 (1.5, 1.9)	5.7 (5.3, 6.1)	11.8 (11.3, 12.3)	22.6 (21.9, 23.3)	28.8 (28.0, 29.6)	32.5 (31.5, 33.4)
Metal/Metal ≤32mm	520	5143	1.6 (1.3, 2.0)	3.3 (2.9, 3.8)	4.4 (3.9, 5.0)	6.8 (6.2, 7.6)	9.6 (8.8, 10.5)	12.0 (11.0, 13.1)
Metal/Non XLPE	3348	36447	1.4 (1.3, 1.6)	2.5 (2.3, 2.7)	3.5 (3.3, 3.7)	6.4 (6.1, 6.7)	10.8 (10.4, 11.2)	15.3 (14.7, 15.8)
Metal/XLPE	8572	217882	1.7 (1.6, 1.7)	2.4 (2.3, 2.5)	3.0 (2.9, 3.1)	4.5 (4.4, 4.6)	6.1 (5.9, 6.2)	7.6 (7.3, 7.9)
Ceramicised Metal/Non XLPE	61	316	1.6 (0.7, 3.8)	3.6 (2.0, 6.4)	3.9 (2.2, 6.8)	12.2 (8.7, 16.9)	21.2 (16.3, 27.2)	31.2 (24.5, 39.3)
Ceramicised Metal/XLPE	1301	41361	1.9 (1.7, 2.0)	2.4 (2.2, 2.5)	2.8 (2.6, 2.9)	3.7 (3.5, 4.0)	4.8 (4.5, 5.2)	5.9 (5.3, 6.5)
TOTAL	29456	633205						

Figure HT45 Cumulative Percent Revision of Primary Total Conventional Hip Replacement by Bearing Surface (Primary Diagnosis OA) HR - adjusted for age and gender

Ceramic/Ceramic vs Ceramic/XLPE

0 - 2Wk: HR=0.96 (95% CI 0.84, 1.09), p=0.525 2Wk - 3Mth: HR=0.74 (95% CI 0.68, 0.80), p<0.001 3Mth - 9Mth: HR=0.90 (95% CI 0.80, 1.01), p=0.063 9Mth - 2.5Yr; HR=1.16 (95% CI 1.07, 1.26), p<0.001 2.5Yr+: HR=1.35 (95% CI 1.27, 1.42), p<0.001

Ceramic/Non XLPE vs Ceramic/XLPE

0 - 3Mth: HR=0.94 (95% CI 0.79, 1.13), p=0.518 3Mth - 8Yr: HR=1.57 (95% CI 1.40, 1.76), p<0.001 8Yr+: HR=3.59 (95% CI 3.19, 4.04), p<0.001

Metal/Metal ≤32mm vs Ceramic/XLPE

0 - 2Wk; HR=1.17 (95% CI 0.72, 1.89), p=0.532 2Wk - 6Mth: HR=0.66 (95% CI 0.48, 0.91), p=0.010 6Mth+: HR=2.07 (95% CI 1.87, 2.28), p<0.001

Metal/Non XLPE vs Ceramic/XLPE

0 - 3Mth: HR=0.75 (95% CI 0.67, 0.85), p<0.001 3Mth - 6Mth: HR=0.99 (95% CI 0.78, 1.26), p=0.954 6Mth - 1.5Yr: HR=1.65 (95% CI 1.45, 1.88), p<0.001 1.5Yr - 3Yr: HR=1.54 (95% CI 1.34, 1.76), p<0.001 3Yr - 8Yr: HR=2.20 (95% CI 2.02, 2.40), p<0.001 8Yr+: HR=3.40 (95% CI 3.16, 3.66), p<0.001

Metal/XLPE vs Ceramic/XLPE

0 - 2Wk: HR=0.95 (95% CI 0.85, 1.07), p=0.394 2Wk - 1Mth: HR=1.13 (95% CI 1.04, 1.23), p=0.005 1Mth - 3Mth: HR=0.99 (95% CI 0.91, 1.07), p=0.737 3Mth - 3Yr: HR=1.12 (95% CI 1.06, 1.18), p<0.001 3Yr+: HR=1.24 (95% CI 1.17, 1.31), p<0.001

Ceramicised Metal/XLPE vs Ceramic/XLPE

0 - 3Mth: HR=1.16 (95% CI 1.05, 1.27), p=0.002 3Mth+: HR=0.83 (95% CI 0.77, 0.90), p<0.001

Metal/Metal > 32mm vs Ceramic/XLPE

0 - 2Wk: HR=1.24 (95% CI 0.94, 1.65), p=0.132 2Wk - 1Mth: HR=0.45 (95% CI 0.31, 0.65), p<0.001 1Mth - 3Mth: HR=0.69 (95% CI 0.52, 0.92), p=0.010 3Mth - 9Mth: HR=1.20 (95% CI 0.94, 1.54), p=0.144 9Mth - 1.5Yr: HR=3.13 (95% CI 2.65, 3.71), p<0.001 1.5Yr - 2Yr: HR=4.95 (95% CI 4.11, 5.96), p<0.001 2Yr - 11Yr: HR=10.48 (95% CI 9.90, 11.09), p<0.001 11Yr+: HR=4.66 (95% CI 4.24, 5.13), p<0.001

₹ 17% From 3 months, OXINIUM/XLPE has the **lowest** risk of revision of all bearing combinations vs ceramic/XLPE (p<0.001)

Comparing the rates of revision for these bearings, Ceramicised Metal/XLPE* has the lowest rate of revision at 20 years. As in previous years, the Registry urges caution in the interpretation of this result. This bearing is a single company product, used with a small number of femoral stem and acetabular component combinations. This may have a confounding effect on the outcome, making it unclear if the lower rate of revision is an effect of the bearing surface or reflects the limited combinations of femoral and acetabular prostheses. Tables and graphs have been reproduced in exact and complete form.


*The term 'Ceramicised Metal/XLPE' is equivalent to 'OXINIUM/XLPE'.



OXINIUM^o/XLPE demonstrates the joint highest survivorship of all bearing combinations at 15 years²

National Joint Registry (NJR) of England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey

 Analysis of 1,026,481 primary THAs, including 21,263 patients with OXINIUM/XLPE over 15 years follow-up (bearing usage from 2003 to 2019)



1.3% Cumulative rates of revision (all cause) for OXINIUM/XLPE were the joint lowest of

all bearings




Figure. Cumulative incidence of revision for any reason and adjusted hazard ratios (HRs) ‡ HRs were adjusted for year of primary surgery, patient gender, age, BMI, ASA physical status grade, implant fixation, shell component materials, stem component materials, and head size at 10 years compared to the reference group (Cobalt Chrome/XLPE primary THA).



OXINIUM/XLPE has the highest 5-year and 9-year survivorship of all bearing combinations³

Dutch Arthroplasty Register (LROI)

Analysis of 209,912 primary THAs with a maximum 10 years' follow-up (bearing usage from 2007 to 2016)

Cumulative rates of revision (all cause) for OXINIUM/(XL)PE were the lowest of all bearings






Figure. Cumulative incidence of revision according to bearing type of THA \S Due to small group sizes, OXINIUM on standard polyethylene (PE) or highly-cross-linked polyethylene (XLPE) were analysed together.



OXINIUM/XLPE has the highest 10-year survivorship of all bearing combinations4

Italian Register of Orthopaedic Prosthetic Implants (RIPO)

Analysis of 20,963 uncemented THAs from 68 orthopaedic units, performed between 2000 and 2015 with 10 years' follow-up








Figure. Revision risk by bearing type at 10 years Insufficient patient numbers at 10 years to estimate failure risk for Ceramic/XLPE. Failure risk of 3.1% calculated

Conclusions

OXINIUM with XLPE has been shown to consistently deliver superior mid- to long-term survivorship and the lowest revision risk compared to all other modern bearing combinations in four arthroplasty registries.

†Acknowledgments: We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.

References: 1. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2025 Annual Report Adelaide; AOA, 2025:1–727. Available at: https://aoanjrr.sahmri.com/annual-reports-2025. Accessed October 2, 2025. 2. Whitehouse MR, Patel R, French JMR, et al. The association of bearing surface materials with the risk of revision following primary total hip replacement: a cohort analysis of 1,026,481 hip replacements from the National Joint Registry, PLoS Med. 2024;21(11):e1004478. 3. Peters RM, Van Steenbergen LN, Stevens M, Rijk PC, Bulstra SK, Zijlstra WP. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthop. 2018:89(2):163–169. 4. Attray A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use